Reference : Reduction comparable des nouveaux cas de diabete de type 2 sous sartan et sous inhibi...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/10240
Reduction comparable des nouveaux cas de diabete de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: comparaison des meta-analyses des essais prospectifs randomises.
French
[en] Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
2005
Revue Médicale de Liège
60
5-6
Le diabète sucré dans tous ses états
424-8
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Benzimidazoles/therapeutic use ; Benzoates/therapeutic use ; Diabetes Mellitus, Type 2/prevention & control ; Heart Failure/complications/drug therapy ; Humans ; Hypertension/complications/drug therapy ; Randomized Controlled Trials as Topic ; Receptors, Angiotensin/physiology
[en] This paper aims at comparing two meta-analyses of clinical trials having investigated the effect of the inhibition of the renin-angiotensin system either with an angiotensin converting enzyme inhibitor (ACEI) or with a selective angiotensin receptor blocker (ARB) on the incidence of new cases of type 2 diabetes mellitus in subjects with arterial hypertension or with congestive heart failure. The protection appears similar with ACEIs in six trials in a total of 24.623 patients (hazard ratio: 0.77; CI 95% 0.72-0.81; p < 0.00001 and with ARBs in five trials in a total of 14.344 patients (hazard ratio: 0.79; CI 95% 0.73-0.85; p < 0.00001). It is consistent whatever the comparator, a thiazide diuretic agent, a beta-blocker, a dihydropyridine calcium channel blocker or a placebo. The large ongoing ONTARGET controlled study will allow a direct comparison between an ACEI, ramipril, and an ARB, telmisartan, and will also investigate the potential benefit of a combined treatment with both drugs. The inhibition of the renin-angiotensin system should be considered among pharmacological strategies of prevention of type 2 diabetes mellitus.
Researchers ; Students
http://hdl.handle.net/2268/10240
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
20050506_29.pdfNo commentaryPublisher postprint555.31 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.